Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 - PubMed (original) (raw)
Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
M S Fung et al. J Virol. 1992 Feb.
Abstract
Two monoclonal antibodies designated BAT085 and G3-136 were raised by immunizing BALB/c mice with gp120 purified from human immunodeficiency virus type 1 (HIV-1) IIIB-infected H9 cell extracts. Among three HIV-1 laboratory isolates (IIIB, MN, and RF), BAT085 neutralized only IIIB infection of CEM-SS cells, whereas G3-136 neutralized both IIIB and RF. These antibodies also neutralized a few primary HIV-1 isolates in the infection of activated human peripheral blood mononuclear cells. In indirect immunofluorescence assays, BAT085 bound to H9 cells infected with IIIB or MN, while G3-136 bound to H9 cells infected with IIIB or RF, but not MN. Using sequence-overlapping synthetic peptides of HIV-1 IIIB gp120, the binding site of BAT085 and G3-136 was mapped to a peptidic segment in the V2 region (amino acid residues 169 to 183). The binding of these antibodies to immobilized gp120 was not inhibited by the antibodies directed to the principal neutralization determinant in the V3 region or to the CD4-binding domain of gp120. In a competition enzyme-linked immunosorbent assay, soluble CD4 inhibited G3-136 but not BAT085 from binding to gp120. Deglycosylation of gp120 by endo-beta-N-acetylglucosaminidase H or reduction of gp120 by dithiothreitol diminished its reactivity with G3-136 but not with BAT085. These results indicate that the V2 region of gp120 contains multiple neutralization determinants recognized by antibodies in both a conformation-dependent and -independent manner.
Similar articles
- Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.
Ho DD, Fung MS, Cao YZ, Li XL, Sun C, Chang TW, Sun NC. Ho DD, et al. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8949-52. doi: 10.1073/pnas.88.20.8949. Proc Natl Acad Sci U S A. 1991. PMID: 1717992 Free PMC article. - Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.
Moore JP, Sattentau QJ, Yoshiyama H, Thali M, Charles M, Sullivan N, Poon SW, Fung MS, Traincard F, Pinkus M, et al. Moore JP, et al. J Virol. 1993 Oct;67(10):6136-51. doi: 10.1128/JVI.67.10.6136-6151.1993. J Virol. 1993. PMID: 7690418 Free PMC article. - Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
Laman JD, Schellekens MM, Abacioglu YH, Lewis GK, Tersmette M, Fouchier RA, Langedijk JP, Claassen E, Boersma WJ. Laman JD, et al. J Virol. 1992 Mar;66(3):1823-31. doi: 10.1128/JVI.66.3.1823-1831.1992. J Virol. 1992. PMID: 1637373 Free PMC article. - Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
Nakamura GR, Byrn R, Wilkes DM, Fox JA, Hobbs MR, Hastings R, Wessling HC, Norcross MA, Fendly BM, Berman PW. Nakamura GR, et al. J Virol. 1993 Oct;67(10):6179-91. doi: 10.1128/JVI.67.10.6179-6191.1993. J Virol. 1993. PMID: 7690420 Free PMC article.
Cited by
- Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure.
Ray K, Mengistu M, Orlandi C, Pazgier M, Lewis GK, DeVico AL. Ray K, et al. Front Immunol. 2019 Jul 5;10:1512. doi: 10.3389/fimmu.2019.01512. eCollection 2019. Front Immunol. 2019. PMID: 31338095 Free PMC article. - Neutralization tiers of HIV-1.
Montefiori DC, Roederer M, Morris L, Seaman MS. Montefiori DC, et al. Curr Opin HIV AIDS. 2018 Mar;13(2):128-136. doi: 10.1097/COH.0000000000000442. Curr Opin HIV AIDS. 2018. PMID: 29266013 Free PMC article. Review. - Expanding role for type I Interferons in restricting HIV growth.
Kent SJ, Kelleher AD. Kent SJ, et al. Immunol Cell Biol. 2017 May;95(5):417-418. doi: 10.1038/icb.2017.15. Epub 2017 Apr 25. Immunol Cell Biol. 2017. PMID: 28440312 No abstract available. - Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robb ML, Michael NL, Kim JH, Zolla-Pazner S, Haynes BF, Mascola JR, Self S, Gilbert P, Montefiori DC. Gottardo R, et al. PLoS One. 2013 Sep 26;8(9):e75665. doi: 10.1371/journal.pone.0075665. eCollection 2013. PLoS One. 2013. PMID: 24086607 Free PMC article. - Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.
Narayan KM, Agrawal N, Du SX, Muranaka JE, Bauer K, Leaman DP, Phung P, Limoli K, Chen H, Boenig RI, Wrin T, Zwick MB, Whalen RG. Narayan KM, et al. PLoS One. 2013;8(1):e52732. doi: 10.1371/journal.pone.0052732. Epub 2013 Jan 9. PLoS One. 2013. PMID: 23326351 Free PMC article.
References
- J Virol. 1988 Aug;62(8):2622-8 - PubMed
- Vaccine. 1988 Jun;6(3):229-32 - PubMed
- AIDS Res Hum Retroviruses. 1987 Summer;3(2):157-63 - PubMed
- J Virol. 1990 Jun;64(6):2833-40 - PubMed
- Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8949-52 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials